Tags

Type your tag names separated by a space and hit enter

Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease.
Mod Rheumatol 2013; 23(3):496-502MR

Abstract

OBJECTIVES

We examined the relationship between disease activity and anti-CADM-140/MDA5 titer measured by enzyme-linked immunosorbent assay (ELISA).

METHODS

Sera from 63 patients with dermatomyositis (DM) [46 classic DM, 17 clinically amyopathic DM (CADM)] were screened for autoantibody using immunoprecipitation assay. Anti-CADM-140/MDA5-positive sera were examined for their titer by anti-CADM-140/MDA5 ELISA. Potential associations between anti-CADM-140/MDA5 titer and clinical course or outcome were analyzed.

RESULTS

Sera from 14 patients with DM (2 classic DM, 12 CADM) had anti-CADM-140/MDA5. Of ten patients with DM and rapidly progressive interstitial lung disease (RP-ILD), the mean titer of anti-CADM-140/MDA5 before treatment was significantly lower in patients who responded to therapy and survived (responder group, n = 4) than in those who did not respond and died (nonresponder group, n = 6) (110.3 vs. 356.9, P = 0.019). In the responder group, the mean titer of anti-CADM-140/MDA5 significantly decreased down to below the cutoff level after treatment (n = 3, 113.4 vs. 1.6, P = 0.033), whereas that of the nonresponder group did not decrease sufficiently and sustained high level (n = 4, 372.5 vs. 198.4, P = 0.31).

CONCLUSIONS

These results emphasize the clinical importance of anti-CADM-140/MDA5 antibody levels to predict outcomes of RP-ILD as well as to monitor disease activity in patients with DM and RP-ILD.

Authors+Show Affiliations

Division of Rheumatology, Department of Internal Medicine, Tokai University School of Medicine, 142 Shimokasuya, Isehara 160-8582, Japan. shinsjam@tokai-u.jpNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

22644102

Citation

Sato, Shinji, et al. "Anti-CADM-140/MDA5 Autoantibody Titer Correlates With Disease Activity and Predicts Disease Outcome in Patients With Dermatomyositis and Rapidly Progressive Interstitial Lung Disease." Modern Rheumatology, vol. 23, no. 3, 2013, pp. 496-502.
Sato S, Kuwana M, Fujita T, et al. Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol. 2013;23(3):496-502.
Sato, S., Kuwana, M., Fujita, T., & Suzuki, Y. (2013). Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Modern Rheumatology, 23(3), pp. 496-502. doi:10.1007/s10165-012-0663-4.
Sato S, et al. Anti-CADM-140/MDA5 Autoantibody Titer Correlates With Disease Activity and Predicts Disease Outcome in Patients With Dermatomyositis and Rapidly Progressive Interstitial Lung Disease. Mod Rheumatol. 2013;23(3):496-502. PubMed PMID: 22644102.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. AU - Sato,Shinji, AU - Kuwana,Masataka, AU - Fujita,Takashi, AU - Suzuki,Yasuo, Y1 - 2012/05/29/ PY - 2012/03/07/received PY - 2012/05/01/accepted PY - 2012/5/31/entrez PY - 2012/5/31/pubmed PY - 2013/12/20/medline SP - 496 EP - 502 JF - Modern rheumatology JO - Mod Rheumatol VL - 23 IS - 3 N2 - OBJECTIVES: We examined the relationship between disease activity and anti-CADM-140/MDA5 titer measured by enzyme-linked immunosorbent assay (ELISA). METHODS: Sera from 63 patients with dermatomyositis (DM) [46 classic DM, 17 clinically amyopathic DM (CADM)] were screened for autoantibody using immunoprecipitation assay. Anti-CADM-140/MDA5-positive sera were examined for their titer by anti-CADM-140/MDA5 ELISA. Potential associations between anti-CADM-140/MDA5 titer and clinical course or outcome were analyzed. RESULTS: Sera from 14 patients with DM (2 classic DM, 12 CADM) had anti-CADM-140/MDA5. Of ten patients with DM and rapidly progressive interstitial lung disease (RP-ILD), the mean titer of anti-CADM-140/MDA5 before treatment was significantly lower in patients who responded to therapy and survived (responder group, n = 4) than in those who did not respond and died (nonresponder group, n = 6) (110.3 vs. 356.9, P = 0.019). In the responder group, the mean titer of anti-CADM-140/MDA5 significantly decreased down to below the cutoff level after treatment (n = 3, 113.4 vs. 1.6, P = 0.033), whereas that of the nonresponder group did not decrease sufficiently and sustained high level (n = 4, 372.5 vs. 198.4, P = 0.31). CONCLUSIONS: These results emphasize the clinical importance of anti-CADM-140/MDA5 antibody levels to predict outcomes of RP-ILD as well as to monitor disease activity in patients with DM and RP-ILD. SN - 1439-7609 UR - https://www.unboundmedicine.com/medline/citation/22644102/Anti_CADM_140/MDA5_autoantibody_titer_correlates_with_disease_activity_and_predicts_disease_outcome_in_patients_with_dermatomyositis_and_rapidly_progressive_interstitial_lung_disease_ L2 - https://dx.doi.org/10.1007/s10165-012-0663-4 DB - PRIME DP - Unbound Medicine ER -